Hormone Optimization: A Clinician-Led Approach

Hormone optimization is having a moment, and most of it is moving in two opposite directions. On one side: telehealth platforms running aggressive testosterone replacement on men who probably don't need it, with minimal monitoring. On the other: a generation of women being told their perimenopausal symptoms are stress, depression, or just "their age."

Both are failures of the same kind. The signal is real. The execution is not.

What hormone optimization actually is

It's the use of bioidentical hormones — testosterone, estrogen, progesterone, thyroid, and sometimes DHEA — to bring patients with documented deficiency or dysregulation back into a physiologically normal range, while monitoring labs and symptoms over time.

Three things matter:

1. The diagnosis is real. Deficiency is diagnosed with labs, symptoms, and clinical context — not a checklist on a website.
2. The dosing is conservative. The goal is physiologic, not supraphysiologic. We're not chasing peak performance; we're restoring function.
3. The monitoring is ongoing. Labs every 3 months for the first year, then 6 to 12 months thereafter. Endpoints matter: not just hormone levels, but what they're driving — body composition, energy, cognition, sleep, libido, recovery, and the safety markers (lipids, hematocrit, PSA in men, breast/endometrial in women).

The case in men

Total testosterone declines roughly 1% per year after age 30. Free testosterone — the bioavailable fraction — often declines faster because SHBG rises with age. By 50, many men have testosterone levels lower than the 25th percentile of healthy 25-year-olds, and many of them feel it: low energy, poor recovery, declining muscle mass and bone density, depressed mood, low libido, and a general loss of edge they sometimes can't quite name.

Done correctly, testosterone replacement therapy in this group restores function. It is not steroid abuse, it is not bodybuilding, and the responsible cardiovascular and prostate data continues to look reassuring in well-monitored patients. But "well-monitored" is the operative phrase. We work it up before starting, dose conservatively, watch hematocrit, lipids, blood pressure, and PSA, and we are willing to taper or stop if the labs or the patient's life situation calls for it.

The case in women

Perimenopause and menopause are not, primarily, a stress or mood disorder. They are an endocrine event. The drop and fluctuation of estradiol and progesterone drive a documented set of symptoms: hot flashes, sleep disruption, brain fog, joint pain, mood changes, vaginal symptoms, and increased risk of osteoporosis and cardiovascular disease.

The Women's Health Initiative scared a generation of physicians off hormone therapy in 2002 based on a study population that wasn't representative of women starting therapy near the menopausal transition. Subsequent reanalysis — and the Endocrine Society and Menopause Society guidelines — have substantially walked that back. For symptomatic women within 10 years of menopause, hormone therapy is generally safe and substantially improves quality of life.

Testosterone in women, by the way, also matters — for libido, energy, and lean mass — and is increasingly recognized as a legitimate component of female hormone optimization.

Where the field gets it wrong

The two failure modes we see most often:

• Overprescribing. Telehealth shops handing out testosterone to men with mid-range labs and a generic "low energy" complaint, with minimal follow-up. These men sometimes feel better short-term and end up with hematocrit elevations, fertility loss, lipid shifts, or a dependency on a therapy they didn't actually need.
• Underprescribing. Symptomatic women told to "wait it out" or handed an SSRI for what is fundamentally a hormone problem. By the time the symptoms are bad enough that everyone agrees, the bone and cardiovascular benefits of starting earlier have been lost.

Our approach

Hormone optimization at TWW is built around a few principles:

• Comprehensive baseline labs, not just total testosterone or a TSH.
• A real conversation about goals, family planning, and risk tolerance before any prescription is written.
• Bioidentical hormones from compounding pharmacies, with delivery routes (transdermal, injection, pellet, oral) chosen to fit the individual.
• Quarterly labs the first year, semi-annual after that.
• An honest willingness to taper or stop when the data or the life context says we should.

Done this way, hormone therapy is one of the most powerful tools we have. Done any other way, it's a problem.